C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 1/00 (2006.01)
Patent
CA 2738781
The invention is in the field of use of engineered microbes for the delivery and administration of therapeutic peptides or proteins to humans or animals suffering from a disease, or the use of engineered microbes for the delivery of antigens such as for vaccination purposes. More in particular, the invention relates to a recombinant microbe that has reduced capacity of colonizing the mucosa in comparison to its wild type ancestor, in particular when residing in the alimentary tract as part of a treatment or vaccination of a human or animal. In particular, the recombinant microbe contains an inactive thymidylate synthase gene that causes the reduced capability for the microbe to colonize in the alimentary tract. The invention also covers the use of said recombinant microbes comprising nucleic acids or vectors for expressing heterologous or homologous proteins; and also for delivery, especially therapeutic delivery, of the said proteins to animals or humans.
Linvention concerne le domaine dutilisation de microbes conçus par génie génétique pour la délivrance et ladministration de peptides ou protéines thérapeutiques à des hommes ou des animaux souffrant dune maladie, ou lutilisation de microbes conçus par génie génétique pour la délivrance dantigènes, par exemple à des fins de vaccination. Plus particulièrement, linvention concerne un microbe recombinant qui a une capacité réduite de colonisation de la muqueuse en comparaison de son ancêtre de type sauvage, notamment lorsquil réside dans le tractus digestif dans le cadre dun traitement ou dune vaccination dun homme ou dun animal. Le microbe recombinant contient notamment un gène thymidylate synthase inactif qui cause la capacité réduite du microbe à coloniser le tractus digestif. Linvention concerne également lutilisation desdits microbes recombinants comprenant des acides nucléiques ou des vecteurs pour exprimer des protéines hétérologues ou homologues ; et également pour la délivrance, notamment la délivrance thérapeutique, desdites protéines à des animaux ou des hommes.
Actogenix N.v.
Borden Ladner Gervais Llp
LandOfFree
Reduced colonization of microbes at the mucosa does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Reduced colonization of microbes at the mucosa, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Reduced colonization of microbes at the mucosa will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-2046249